PDCD1 and Merkel cell skin cancer: Pembrolizumab (30) (α-PD-1) and avelumab (31, 52) (α-PD-L1) are approved for the treatment of metastatic MCC, with nivolumab (α-PD-1) currently being evaluated in clinical trials (53).